CAMBREX LICENSES CELL LINE TO CHUGAI PHARMACEUTICAL CO

Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex (NYSE: CBM) and the world's leading provider of cell systems, announced today that its client Chugai Pharmaceutical Co., Ltd. completed their assessment of certain of its Clonetics(R) Conditionally Immortalized Cell Lines under the previously announced evaluation license and signed a one-year renewable license agreement to use a cell line in Chugai pharmaceutical drug discovery programs. Chugai is the first company to license this technology in Japan.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-21-2006/0004286462&EDATE=)